A randomized trial of icatibant in ACE-inhibitor-induced angioedema.

BACKGROUND Angioedema induced by treatment with angiotensin-converting-enzyme (ACE) inhibitors accounts for one third of angioedema cases in the emergency room; it is usually manifested in the upper airway and the head and neck region. There is no approved treatment for this potentially life-threatening condition. METHODS In this multicenter, double-blind, double-dummy, randomized phase 2 study, we assigned patients who had ACE-inhibitor-induced angioedema of the upper aerodigestive tract to treatment with 30 mg of subcutaneous icatibant, a selective bradykinin B2 receptor antagonist, or to the current off-label standard therapy consisting of intravenous prednisolone (500 mg) plus clemastine (2 mg). The primary efficacy end point was the median time to complete resolution of edema. RESULTS All 27 patients in the per-protocol population had complete resolution of edema. The median time to complete resolution was 8.0 hours (interquartile range, 3.0 to 16.0) with icatibant as compared with 27.1 hours (interquartile range, 20.3 to 48.0) with standard therapy (P=0.002). Three patients receiving standard therapy required rescue intervention with icatibant and prednisolone; 1 patient required tracheotomy. Significantly more patients in the icatibant group than in the standard-therapy group had complete resolution of edema within 4 hours after treatment (5 of 13 vs. 0 of 14, P=0.02). The median time to the onset of symptom relief (according to a composite investigator-assessed symptom score) was significantly shorter with icatibant than with standard therapy (2.0 hours vs. 11.7 hours, P=0.03). The results were similar when patient-assessed symptom scores were used. CONCLUSIONS Among patients with ACE-inhibitor-induced angioedema, the time to complete resolution of edema was significantly shorter with icatibant than with combination therapy with a glucocorticoid and an antihistamine. (Funded by Shire and the Federal Ministry of Education and Research of Germany; ClinicalTrials.gov number, NCT01154361.).

[1]  D. Launay,et al.  Prise en charge des angiœdèmes induits par les inhibiteurs de l’enzyme de conversion de l’angiotensine : recommandations du Centre de référence national des angiœdèmes , 2013 .

[2]  B. Floccard,et al.  [Management of angiotensin-converting enzyme inhibitor-related angioedema: recommendations from the French National Center for Angioedema]. , 2013, La Revue de medecine interne.

[3]  Adrian F Hernandez,et al.  Comparative risk for angioedema associated with the use of drugs that target the renin-angiotensin-aldosterone system. , 2012, Archives of internal medicine.

[4]  M. van Deuren,et al.  Bradykinin-receptor antagonist icatibant: possible treatment for ACE inhibitor-related angio-oedema. , 2012, The Netherlands journal of medicine.

[5]  M. Gallitelli,et al.  Icatibant: a novel approach to the treatment of angioedema related to the use of angiotensin-converting enzyme inhibitors. , 2012, The American journal of emergency medicine.

[6]  T. Ovesen,et al.  Increasing rate of angiotensin-converting enzyme inhibitor-related upper airway angio-oedema. , 2012, Danish medical journal.

[7]  G. Kojda,et al.  [Angiotensin-converting enzyme inhibitor induced angioedema : new therapy options]. , 2011, Der Anaesthesist.

[8]  F. Lapostolle,et al.  Angiœdème bradykinique secondaire aux inhibiteurs de l’enzyme de conversion : instaurer le traitement en préhospitalier , 2011 .

[9]  F. Lapostolle,et al.  [Bradykinin-mediated angioedema secondary to angiotensin converting enzyme: initiate treatment from the prehospital phase]. , 2011, Annales francaises d'anesthesie et de reanimation.

[10]  F. Trautinger,et al.  Treatment of angiotensin-converting enzyme inhibitor-related angioedema with the bradykinin B2 receptor antagonist icatibant. , 2010, Journal of the American Academy of Dermatology.

[11]  G. Kojda,et al.  Therapeutic efficacy of icatibant in angioedema induced by angiotensin-converting enzyme inhibitors: a case series. , 2010, Annals of emergency medicine.

[12]  William H. Yang,et al.  Icatibant, a new bradykinin-receptor antagonist, in hereditary angioedema. , 2010, The New England journal of medicine.

[13]  F. Marceau,et al.  Angiotensin converting enzyme inhibitor induced angio‐oedema: a review of the pathophysiology and risk factors , 2009, Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology.

[14]  Donald R. Miller,et al.  Angioedema Incidence in US Veterans Initiating Angiotensin-Converting Enzyme Inhibitors , 2008, Hypertension.

[15]  C. Camargo,et al.  Multicenter study of patients with angiotensin-converting enzyme inhibitor-induced angioedema who present to the emergency department. , 2008, Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology.

[16]  G. Kojda,et al.  [ACE inhibitor-induced angioedema in the head and neck region. A matter of time?]. , 2004, HNO.

[17]  H. Black,et al.  Omapatrilat and enalapril in patients with hypertension: the Omapatrilat Cardiovascular Treatment vs. Enalapril (OCTAVE) trial. , 2004, American journal of hypertension.

[18]  M. Bas,et al.  Durch ACE-Hemmer induziertes Angioödem des Kopf-Hals-Bereichs , 2004, HNO.

[19]  D. L. Schultz,et al.  Asphyxia due to angiotensin converting enzyme (ACE) inhibitor mediated angioedema of the tongue during the treatment of hypertensive heart disease. , 2001, Journal of forensic sciences.

[20]  J. Morrow,et al.  Effect of bradykinin-receptor blockade on the response to angiotensin-converting-enzyme inhibitor in normotensive and hypertensive subjects. , 1998, The New England journal of medicine.

[21]  B. Stricker,et al.  ACE Inhibitor-Induced Angioedema , 1998, Drug safety.

[22]  B. Fanburg,et al.  Stimulation of bovine pulmonary artery endothelial cell ACE by dexamethasone: involvement of steroid receptors. , 1992, The American journal of physiology.

[23]  F. Soubrier,et al.  Structure of the angiotensin I-converting enzyme gene. Two alternate promoters correspond to evolutionary steps of a duplicated gene. , 1991, The Journal of biological chemistry.

[24]  W. Inman,et al.  Clinical profile of angioedema associated with angiotensin converting-enzyme inhibition. , 1988, JAMA.